GlassScriptPhysician profile
Biron D Baker
NPI 1124081658
$7,974.04
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,597 · 2021: $1,953 · 2022: $1,887 · 2023: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $783.38 | 2019-2023 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $739.78 | 2019-2023 | Farxiga, Breztri |
| Astellas Pharma US INC | $606.21 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $596.02 | 2019-2023 | Nucala |
| Lilly USA, LLC | $579.22 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $539.21 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $460.26 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Allergan, INC. | $391.09 | 2019-2020 | |
| Pfizer INC. | $383.96 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $335.21 | 2019-2023 | Trintellix |
| Amgen INC. | $293.68 | 2019-2023 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $266.25 | 2020-2022 | |
| Lundbeck LLC | $239.75 | 2020-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $219.54 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $197.50 | 2019-2023 | Spravato |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biron Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.